Evidence map›Paper›PMID 31659326›Full record

ArticleNature methods2019

Biological plasticity rescues target activity in CRISPR knock outs.

Arne H Smits, Frederik Ziebell, Gerard Joberty, Nico Zinn, William F Mueller, Sandra Clauder-Münster, Dirk Eberhard, Maria Fälth Savitski, Paola Grandi, Petra Jakob and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed.

  1. Frameshift Mutations in Exon 1 ofJournal of developmental biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Arne H Smits *European Molecular Biology Laboratory, Heidelberg, Germany.
Frederik Ziebell *European Molecular Biology Laboratory, Heidelberg, Germany.
Gerard JobertyCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.
Nico ZinnCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.
William F MuellerEuropean Molecular Biology Laboratory, Heidelberg, Germany.
Sandra Clauder-MünsterEuropean Molecular Biology Laboratory, Heidelberg, Germany.
Dirk EberhardCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6662-4105
Maria Fälth SavitskiCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.
Paola GrandiCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.
Petra JakobEuropean Molecular Biology Laboratory, Heidelberg, Germany.
Anne-Marie MichonCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.
Hanice SunDepartment of Genetics and Stanford Genome Technology Center, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3390-0027
Karen TessmerEuropean Molecular Biology Laboratory, Heidelberg, Germany.
Tilmann BürckstümmerAelian Biotechnology, Vienna, Austria.
Marcus BantscheffCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8343-8977
Lars M SteinmetzEuropean Molecular Biology Laboratory, Heidelberg, Germany. lars.steinmetz@embl.de.
Gerard DrewesCellzome, Functional Genomics Research and Development, GlaxoSmithKline, Heidelberg, Germany. gerard.c.drewes@gsk.com.
Wolfgang HuberEuropean Molecular Biology Laboratory, Heidelberg, Germany. wolfgang.huber@embl.de.ORCID http://orcid.org/0000-0002-0474-2218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene knock outs (KOs) are efficiently engineered through CRISPR-Cas9-induced frameshift mutations. While the efficiency of DNA editing is readily verified by DNA sequencing, a systematic understanding of the efficiency of protein elimination has been lacking. Here we devised an experimental strategy combining RNA sequencing and triple-stage mass spectrometry to characterize 193 genetically verified deletions targeting 136 distinct genes generated by CRISPR-induced frameshifts in HAP1 cells. We observed residual protein expression for about one third of the quantified targets, at variable levels from low to original, and identified two causal mechanisms, translation reinitiation leading to N-terminally truncated target proteins or skipping of the edited exon leading to protein isoforms with internal sequence deletions. Detailed analysis of three truncated targets, BRD4, DNMT1 and NGLY1, revealed partial preservation of protein function. Our results imply that systematic characterization of residual protein expression or function in CRISPR-Cas9-generated KO lines is necessary for phenotype interpretation.

Indexed as

Gene Knockout TechniquesBromodomain Containing ProteinsCell Cycle ProteinsCRISPR-Cas SystemsDNA (Cytosine-5-)-Methyltransferase 1ExonsHumansMutationPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanNGLY1 protein, humanPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseTranscription Factors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.